BIOCARTIS RECEIVES € 1,7M IWT GRANT FOR IMPROVED DISEASE DIAGNOSIS

FlandersBio's picture
Printer-friendly versionPrinter-friendly versionPDF versionPDF version

27/06/2014

Biocartis announced today it received a grant of € 1.7M from the Flemish Government to further enhance the capabilities of its flagship platform Idylla™ (1). With this grant the Flemish Agency for Innovation by Science and Technology (IWT) affirms its belief in Biocartis’ cutting edge R&D.

Biocartis will use this grant to develop, amongst others, its hybrid multiplexing technology aimed at detecting and quantifying multiple biomarker types with a single Idylla™ test. Biocartis is currently developing oncology assays that can already detect tens of biomarkers of the same type. Looking ahead, Biocartis is working on the detection of multiple biomarker types in a single test. Today this can only be accomplished by using several individual tests, often performed on different diagnostic systems or even in separate laboratories, making it a very costly process. The hybrid multiplexing technology opens the door to cost-effective, simultaneous testing of several actionable biomarkers from a single patient sample, allowing precision medicine at affordable cost.

Geert Maertens, Chief Scientific Officer at Biocartis, stated: “The hybrid multiplexing project will strengthen our competitive position in the oncology field and open new opportunities in other disease areas such as infectious and genetic diseases”.

News Source : BIOCARTIS RECEIVES € 1,7M IWT GRANT FOR IMPROVED DISEASE DIAGNOSIS
Copy this html code to your website/blog to embed this press release.